Table 1.
Patient and treatment characteristics.
| Patient | Age [years] | Sex | Karnofsky performancescore [%] | Clinical T N stage | UICC stage | Histology | GTV [cm3] | Radiotherapy dose (TD, SD) [Gy] | Chemotherapy | Agent |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 57.5 | m | 80 | T4N3 | IIIC | SCC | 261.7 | 66, 2 | yes | carboplatin/vinorelbine |
| 2 | 62.6 | m | 80 | T3N1 | IIIA | Adeno-CA | 185.2 | 64, 2 | yes | carboplatin/pemetrexed |
| 3 | 69.7 | m | 70 | T4N3 | IIIC | SCC | 186.8 | 66, 2 | yes | carboplatin/vinorelbine |
| 4 | 81.6 | f | 80 | T4N2 | IIIB | SCC | 99.7 | 60, 2 | yes | carboplatin/vinorelbine |
| 5 | 74.7 | m | 80 | T4N0 | IIIA | SCC | 179.0 | 66, 2 | no | |
| 6 | 63.6 | m | 80 | T4N1 | IIIA | Adeno-CA | 154.4 | 60, 2 | yes | carboplatin/vinorelbine |
| 7 | 79.0 | m | 60 | T4N1 | IIIA | Adeno-Ca | 496.8 | 66, 2 | no | |
| 8 | 54.1 | f | 80 | T4N3 | IIIC | Adeno-Ca | 383.1 | 60, 2 | no | |
| 9 | 57.7 | f | 90 | T4N3 | IIIC | Adeno-Ca | 124.0 | 60, 2 | yes | carboplatin/vinorelbine |
| 10 | 86.5 | f | 70 | T4N1 | IIIA | SCC | 220.5 | 66, 2 | no |
F, female; m, male; Adeno-CA, adenocarcinoma; SCC, squamous cell carcinoma; GTV, gross tumor volume in planning CT; TD, total dose; SD, single dose; Gy, Gray.